Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and
vascular permeability. Increased serum VEGF concentrations (S‐VEGF) have been found in …

… status of the epidermal growth factor receptor (EGFR) has resulted in an improvement in the
treatment of non-small cell lung cancer. In contrast, small cell lung cancer (SCLC) continues …

… Like most cancers, lung cancer is a conglomeration … -cell lung cancer (SCLC, comprising
20% of lung cancers), and non-small-cell lung cancer (NSCLC, comprising 80% of lung cancers…

… Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

… Mutations of epidermal growth factor receptor in the current study. Numbers in parentheses
indicate the number of patients with the mutation. Exons 18, 19, 21, and 23 were analyzed in …

… in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine
kinase inhibitors gefitinib and erlotinib in patients with advanced non–small-cell lung cancer. …

… been found to be effective against lung cancer in vitro, but clinical resistance to … growth
factor I (IGF-I) signaling pathway induces resistance of non–small cell lung cancer (NSCLC) cells …

… specimens from 109 patients with previously untreated squamous cell lung … growth factor
(VEGF) and its receptor Flt-1. Our analysis attempted to determine whether these factors have …

… Epidermal growth factor receptor overexpression is pronounced in virtually all squamous …
65% of large cell and adenocarcinomas. It is not expressed in situ by small cell lung carcinoma. …

… growth factor (EGF) receptors (EGFRs) and EGF family ligands in non-small-cell lung cancer
(… (TKIs) such as gefitinib exhibit limited activity in this cancer. We propose that autocrine …